630 related articles for article (PubMed ID: 15753533)
1. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
2. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
3. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
4. In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD.
Memoli B; Grandaliano G; Soccio M; Postiglione L; Guida B; Bisesti V; Esposito P; Procino A; Marrone D; Michael A; Andreucci M; Schena FP; Pertosa G
J Am Soc Nephrol; 2005 Apr; 16(4):1099-107. PubMed ID: 15716332
[TBL] [Abstract][Full Text] [Related]
5. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
6. [Soluble cytokinin receptors in renal vasculitis and lupus nephritis].
Tesar V; Jirsa M; Masek Z; Bartůnková J; Stejskalová A; Dostál C; Zabka J; Chábová V; Rysavá R
Cas Lek Cesk; 1998 May; 137(9):271-5. PubMed ID: 9650355
[TBL] [Abstract][Full Text] [Related]
7. [Determination of serum soluble interleukin-6 receptor and soluble gp130 levels in patient with pregnancy induced hypertension and its significance].
Li Y; Wang Y; Qi L
Zhonghua Fu Chan Ke Za Zhi; 2001 Jan; 36(1):18-9. PubMed ID: 11778537
[TBL] [Abstract][Full Text] [Related]
8. Soluble cytokine receptors in renal vasculitis and lupus nephritis.
Tesar V; Jirsa M; Zima T; Kalousová M; Bartunková J; Stejskalová A; Dostál C; Zabka J
Med Sci Monit; 2002 Jan; 8(1):BR24-9. PubMed ID: 11782670
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction.
Jouvenne P; Vannier E; Dinarello CA; Miossec P
Arthritis Rheum; 1998 Jun; 41(6):1083-9. PubMed ID: 9627018
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
Nagaoka T; Sato S; Hasegawa M; Ihn H; Takehara K
J Rheumatol; 2000 Aug; 27(8):1917-21. PubMed ID: 10955333
[TBL] [Abstract][Full Text] [Related]
12. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
Nielsen OH; Ciardelli T; Wu Z; Langholz E; Kirman I
Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
[TBL] [Abstract][Full Text] [Related]
13. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis.
Olsen T; Goll R; Cui G; Husebekk A; Vonen B; Birketvedt GS; Florholmen J
Scand J Gastroenterol; 2007 Nov; 42(11):1312-20. PubMed ID: 17852866
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory cytokines and soluble receptors after coronary artery bypass grafting.
Wei M; Kuukasjärvi P; Laurikka J; Pehkonen E; Kaukinen S; Laine S; Tarkka M
Cytokine; 2001 Aug; 15(4):223-8. PubMed ID: 11563882
[TBL] [Abstract][Full Text] [Related]
16. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression.
Oh JW; Van Wagoner NJ; Rose-John S; Benveniste EN
J Immunol; 1998 Nov; 161(9):4992-9. PubMed ID: 9794436
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
18. [Changes of proinflammatory cytokines and their receptors in serum from patients with pulmonary tuberculosis].
Tang S; Xiao H; Fan Y; Wu F; Zhang Z; Li H; Yang Y
Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):325-9. PubMed ID: 12126553
[TBL] [Abstract][Full Text] [Related]
19. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids.
Arend WP; Malyak M; Smith MF; Whisenand TD; Slack JL; Sims JE; Giri JG; Dower SK
J Immunol; 1994 Nov; 153(10):4766-74. PubMed ID: 7963543
[TBL] [Abstract][Full Text] [Related]
20. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies.
Koss K; Satsangi J; Fanning GC; Welsh KI; Jewell DP
Genes Immun; 2000 Feb; 1(3):185-90. PubMed ID: 11196710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
